1. Home
  2. MEG vs PHAT Comparison

MEG vs PHAT Comparison

Compare MEG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montrose Environmental Group Inc.

MEG

Montrose Environmental Group Inc.

HOLD

Current Price

$22.14

Market Cap

930.8M

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$12.38

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEG
PHAT
Founded
2012
2018
Country
United States
United States
Employees
3500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
930.8M
894.0M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
MEG
PHAT
Price
$22.14
$12.38
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$35.25
$19.83
AVG Volume (30 Days)
238.0K
1.3M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
93.69
42.72
EPS
N/A
N/A
Revenue
$830,538,000.00
$175,110,000.00
Revenue This Year
$5.41
$93.04
Revenue Next Year
$7.19
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
19.26
216.93
52 Week Low
$19.00
$3.69
52 Week High
$32.00
$18.31

Technical Indicators

Market Signals
Indicator
MEG
PHAT
Relative Strength Index (RSI) 52.09 52.44
Support Level $20.80 $10.38
Resistance Level $23.48 $12.52
Average True Range (ATR) 0.79 1.00
MACD 0.13 -0.01
Stochastic Oscillator 88.92 77.58

Price Performance

Historical Comparison
MEG
PHAT

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: